Lupin Divests U.S. Commercial Women's Health Specialty Business To Evofem Biosciences
2024-07-14
3995
(fxcue news) - Pharma major Lupin Ltd. announced Monday that it has divested its U.S. Commercial Women's Health Specialty Business to Evofem Biosciences, Inc. (EVFM), a U.S. biopharmaceutical company focused exclusively on Women's Health.
Lupin's U.S. Commercial Women's Health Specialty Business is primarily focused on commercializing SOLOSEC (secnidazole) 2g oral granules.
This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.
Sign In via X
Google
Sign In via Google
This page link:http://www.fxcue.com/32080.html
Tips:This page came from Internet, which is not standing for FXCUE opinions of this website.
Statement:Contact us if the content violates the law or your rights